Patrick John  Finn net worth and biography

Patrick Finn Biography and Net Worth

Insider of Twist Bioscience
Patrick has a strong track record of high-growth sales in bioreagent, B2B and custom manufacturing organizations. His technical background paired with his ability to identify customer's unmet needs make him the ideal fit to lead our commercial organization. Before Twist Bioscience, Paddy served as Vice President of Sales and Marketing for Enzymatics (recently acquired by QIAGEN), leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers. Prior to Enzymatics, Paddy held positions with increasing commercial focus, including Director of Business Development at Agilent Technologies, Director of Product Development for Beckman Coulter Molecular Diagnostics, and multiple technical roles in product development within Invitrogen and GE Healthcare/Amersham International. In addition, Paddy currently serves on the Scientific Advisory Board of Lasergen and previously served on the Scientific Advisory Board of Enzymatics. He holds a PhD in Nucleic Acid Chemistry from Southampton University and a BSc Hons in Chemistry from Heriot-Watt University.

What is Patrick John Finn's net worth?

The estimated net worth of Patrick John Finn is at least $1.36 million as of September 2nd, 2021. Dr. Finn owns 40,181 shares of Twist Bioscience stock worth more than $1,359,323 as of March 19th. This net worth approximation does not reflect any other assets that Dr. Finn may own. Additionally, Dr. Finn receives a salary of $943,940.00 as Insider at Twist Bioscience. Learn More about Patrick John Finn's net worth.

How old is Patrick John Finn?

Dr. Finn is currently 52 years old. There are 6 older executives and no younger executives at Twist Bioscience. The oldest executive at Twist Bioscience is Dr. William Charles Banyai Ph.D., Senior VP of Advanced Development, GM of Data Storage & Director, who is 69 years old. Learn More on Patrick John Finn's age.

What is Patrick John Finn's salary?

As the Insider of Twist Bioscience Co., Dr. Finn earns $943,940.00 per year. The highest earning executive at Twist Bioscience is Dr. Emily Marine Leproust Ph.D., Co-Founder, Chairman & CEO, who commands a salary of $1,370,000.00 per year. Learn More on Patrick John Finn's salary.

How do I contact Patrick John Finn?

The corporate mailing address for Dr. Finn and other Twist Bioscience executives is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. Twist Bioscience can also be reached via phone at (800) 719-0671 and via email at [email protected]. Learn More on Patrick John Finn's contact information.

Has Patrick John Finn been buying or selling shares of Twist Bioscience?

Patrick John Finn has not been actively trading shares of Twist Bioscience in the last ninety days. Most recently, Patrick John Finn sold 659 shares of the business's stock in a transaction on Tuesday, February 1st. The shares were sold at an average price of $60.52, for a transaction totalling $39,882.68. Learn More on Patrick John Finn's trading history.

Who are Twist Bioscience's active insiders?

Twist Bioscience's insider roster includes William Banyai (Insider), Robert Chess (Director), Keith Crandell (Director), Mark Daniels (Insider), Patrick Finn (Insider), Paula Green (SVP), Jan Johannessen (Director), Emily Leproust (CEO), James Thorburn (CFO), and Patrick Weiss (COO). Learn More on Twist Bioscience's active insiders.

Are insiders buying or selling shares of Twist Bioscience?

In the last year, Twist Bioscience insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $132,000.00. In the last year, insiders at the sold shares 6 times. They sold a total of 6,743 shares worth more than $242,057.80. The most recent insider tranaction occured on March, 14th when insider Dennis Cho sold 93 shares worth more than $3,217.80. Insiders at Twist Bioscience own 3.9% of the company. Learn More about insider trades at Twist Bioscience.

Information on this page was last updated on 3/14/2024.

Patrick John Finn Insider Trading History at Twist Bioscience

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2022Sell659$60.52$39,882.68View SEC Filing Icon  
12/29/2021Sell5,994$75.62$453,266.28View SEC Filing Icon  
12/21/2021Sell219$82.85$18,144.15View SEC Filing Icon  
12/2/2021Sell1,758$88.04$154,774.32View SEC Filing Icon  
11/2/2021Sell1,758$127.23$223,670.34View SEC Filing Icon  
10/4/2021Sell2,702$104.27$281,737.54View SEC Filing Icon  
9/2/2021Sell2,702$117.99$318,808.9840,181View SEC Filing Icon  
7/2/2021Sell2,702$131.70$355,853.4041,155View SEC Filing Icon  
6/2/2021Sell2,702$104.64$282,737.2841,770View SEC Filing Icon  
5/4/2021Sell2,702$117.39$317,187.7842,797View SEC Filing Icon  
4/5/2021Sell2,702$126.72$342,397.4443,102View SEC Filing Icon  
1/5/2021Sell2,702$132.93$359,176.8644,586View SEC Filing Icon  
12/7/2020Sell25,845$131.46$3,397,583.7050,424View SEC Filing Icon  
8/27/2020Sell2,358$67.22$158,504.7638,098View SEC Filing Icon  
7/23/2020Sell2,358$59.11$139,381.3838,441View SEC Filing Icon  
7/6/2020Sell11,336$46.69$529,277.8426,361View SEC Filing Icon  
7/2/2020Sell1,400$46.68$65,352.0037,697View SEC Filing Icon  
5/28/2020Sell2,116$37.09$78,482.4438,615View SEC Filing Icon  
1/22/2020Sell15,000$22.52$337,800.0031,466View SEC Filing Icon  
11/27/2019Sell36,932$23.83$880,089.56
10/24/2019Sell33,000$25.01$825,330.00
9/26/2019Sell37,000$25.43$940,910.00
See Full Table

Patrick John Finn Buying and Selling Activity at Twist Bioscience

This chart shows Patrick John Finn's buying and selling at Twist Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Twist Bioscience Company Overview

Twist Bioscience logo
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $33.83
Low: $32.87
High: $34.52

50 Day Range

MA: $36.65
Low: $32.28
High: $41.50

2 Week Range

Now: $33.83
Low: $11.46
High: $43.21

Volume

634,175 shs

Average Volume

995,473 shs

Market Capitalization

$1.96 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64